Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence:: a systematic review

被引:352
作者
Carmen, B [1 ]
Angeles, M [1 ]
Ana, M [1 ]
María, AJ [1 ]
机构
[1] Inst Salud Carlos 3, Agcy Hlth Technol Assessment, Madrid 28029, Spain
关键词
acamprosate; alcohol dependence; alcoholism treatment; meta-analysis; naltrexone;
D O I
10.1111/j.1360-0443.2004.00763.x
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Aims To ascertain the efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence. Methods Systematic review of the literature (1990-2002) and meta-analysis of full published randomized and controlled clinical trials assessing acamprosate or naltrexone therapy in alcohol dependence. Estimates of effect were calculated according to the fixed-effects model. Measurements Relapse and abstinence rates, cumulative abstinence duration and treatment compliance were considered as primary outcomes. Findings Thirty-three studies met the inclusion criteria. Acamprosate was associated with a significant improvement in abstinence rate [odds ratio (OR): 1.88 (1.57, 2.25), P < 0.001] and days of cumulative abstinence [WMD: 26.55 (17.56, 36.54]. Short-term administration of naltrexone reduced the relapse rate significantly [OR: 0.62 (0.52, 0.75),P<0.001], but was not associated with a significant modification in the abstinence rate [OR: 1.26 (0.97, 1.64), P = 0.08]. There were insufficient data to ascertain naltrexone's efficacy over more prolonged periods. Acamprosate had a good safety pattern and was associated with a significant improvement in treatment compliance [OR: 1.29 (L 13, 1.47), P<0.001]. Naltrexone's side effects were more numerous, yet the drug was nevertheless tolerated acceptably without being associated with a lower adherence to treatment (OR: 0.94 (0.80, 1.1), P = 0.5). However, overall compliance was relatively low with both medications. Conclusions Both acamprosate and naltrexone are effective as adjuvant therapies for alcohol dependence in adults. Acamprosate appears to be especially useful in a therapeutic approach targeted at achieving abstinence, whereas naltrexone seems more indicated in programmes geared to controlled consumption. Both drugs are safe and acceptably tolerated but issues of compliance need to be addressed adequately to assure their usefulness in clinical practice.
引用
收藏
页码:811 / 828
页数:18
相关论文
共 75 条
[21]   Acamprosate and prevention of relapse in alcoholics - Results of a randomized, placebo-controlled, double-blind study in out-patient alcoholics in the Netherlands, Belgium and Luxembourg [J].
Geerlings, PJ ;
Ansoms, C ;
vandenBrink, W .
EUROPEAN ADDICTION RESEARCH, 1997, 3 (03) :129-137
[22]   INVITED COMMENTARY - A CRITICAL-LOOK AT SOME POPULAR METAANALYTIC METHODS [J].
GREENLAND, S .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1994, 140 (03) :290-296
[23]   Acamprosate during and after acute alcohol withdrawal: A double-blind placebo-controlled study in spain [J].
Gual, A ;
Lehert, P .
ALCOHOL AND ALCOHOLISM, 2001, 36 (05) :413-418
[24]   A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder:: Results from a multicenter clinical trial [J].
Guardia, J ;
Caso, C ;
Arias, F ;
Gual, A ;
Sanahuja, J ;
Ramírez, M ;
Mengual, I ;
Gonzalvo, B ;
Segura, L ;
Trujols, J ;
Casas, M .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2002, 26 (09) :1381-1387
[25]   Rating the quality of evidence for clinical practice guidelines [J].
Hadorn, DC ;
Baker, D ;
Hodges, JS ;
Hicks, N .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1996, 49 (07) :749-754
[26]   Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence:: A factorial double-blind, placebo-controlled trial [J].
Heinälä, P ;
Alho, H ;
Kiianma, K ;
Lönnqvist, J ;
Kuoppasalmi, K ;
Sinclair, JD .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (03) :287-292
[27]   Naltrexone treatment of comorbid alcohol and cocaine use disorders [J].
Hersh, D ;
Van Kirk, JR ;
Kranzler, HR .
PSYCHOPHARMACOLOGY, 1998, 139 (1-2) :44-52
[28]   Relapse prevention in alcoholics - A review of acamprosate versus naltrexone [J].
Hoes, MJAJM .
CLINICAL DRUG INVESTIGATION, 1999, 17 (03) :211-216
[29]   Alcoholism treatment and medical care costs from Project MATCH [J].
Holder, HD ;
Cisler, RA ;
Longabaugh, R ;
Stout, RL ;
Treno, AJ ;
Zweben, A .
ADDICTION, 2000, 95 (07) :999-1013
[30]   The need for caution in interpreting high quality systematic reviews [J].
Hopayian, K .
BRITISH MEDICAL JOURNAL, 2001, 323 (7314) :681-684